Evidence map›Paper›PMID 26626714›Full record

ArticleRadiation oncology (London, England)2015

Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.

Imran H Chowdhury, Eric Ojerholm, Matthew T McMillan, Denise Miller, James D Kolker, Goldie Kurtz, Jay F Dorsey, Suneel N Nagda, Geoffrey A Geiger, Steven Brem and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Melanoma Brain Metastasis: Mechanisms, Models, and Medicine.International journal of molecular sciences · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Imran H ChowdhuryDepartment of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard - TRC 2 West, Philadelphia, 19104, PA, USA. Imran.Chowdhury@uphs.upenn.edu.
Eric OjerholmDepartment of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard - TRC 2 West, Philadelphia, 19104, PA, USA. Eric.Ojerholm@uphs.upenn.edu.
Matthew T McMillanDepartment of Surgery, University of Pennsylvania, 3400 Spruce Street, 4 Silverstein, Philadelphia, 19104, PA, USA. Matthew.Mcmillan@uphs.upenn.edu.
Denise MillerDepartment of Neurosurgery, University of Pennsylvania, 3400 Spruce Street - 3 Silverstein, Philadelphia, 19104, PA, USA. Denise.Miller2@uphs.upenn.edu.
James D KolkerDepartment of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard - TRC 2 West, Philadelphia, 19104, PA, USA. James.Kolker@uphs.upenn.edu.
Goldie KurtzDepartment of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard - TRC 2 West, Philadelphia, 19104, PA, USA. Goldie.Kurtz@uphs.upenn.edu.
Jay F DorseyDepartment of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard - TRC 2 West, Philadelphia, 19104, PA, USA. Jay.Dorsey2@uphs.upenn.edu.
Suneel N NagdaDepartment of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard - TRC 2 West, Philadelphia, 19104, PA, USA. Suneel.Nagda@uphs.upenn.edu.
Geoffrey A GeigerDepartment of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard - TRC 2 West, Philadelphia, 19104, PA, USA. Geoffrey.Geiger@uphs.upenn.edu.
Steven BremDepartment of Neurosurgery, University of Pennsylvania, 3400 Spruce Street - 3 Silverstein, Philadelphia, 19104, PA, USA. Steven.Brem@uphs.upenn.edu.
Donald M O'RourkeDepartment of Neurosurgery, University of Pennsylvania, 3400 Spruce Street - 3 Silverstein, Philadelphia, 19104, PA, USA. orourked@mail.med.upenn.edu.
Eric L ZagerDepartment of Neurosurgery, University of Pennsylvania, 3400 Spruce Street - 3 Silverstein, Philadelphia, 19104, PA, USA. Eric.Zager@uphs.upenn.edu.
Tara GangadharDepartment of Medicine, Division of Hematology/Oncology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, 19104, PA, USA. Tara.Gangadhar@uphs.upenn.edu.
Lynn SchuchterDepartment of Medicine, Division of Hematology/Oncology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, 19104, PA, USA. Lynn.Schuchter@uphs.upenn.edu.
John Y K LeeDepartment of Neurosurgery, University of Pennsylvania, 3400 Spruce Street - 3 Silverstein, Philadelphia, 19104, PA, USA. John.Lee3@uphs.upenn.edu.
Michelle Alonso-BasantaDepartment of Radiation Oncology, University of Pennsylvania, 3400 Civic Center Boulevard - TRC 2 West, Philadelphia, 19104, PA, USA. Michelle.Alonso-Basanta@uphs.upenn.edu.
University of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStereotactic radiosurgery (SRS) alone is an increasingly common treatment strategy for brain metastases. However, existing prognostic tools for overall survival (OS) were developed using cohorts of patients treated predominantly with approaches other than SRS alone. Therefore, we devised novel risk scores for OS and distant brain failure (DF) for melanoma brain metastases (MBM) treated with SRS alone. METHODS AND MATERIALS: We retrospectively reviewed 86 patients treated with SRS alone for MBM from 2009-2014. OS and DF were estimated using the Kaplan-Meier method. Cox proportional hazards modeling identified clinical risk factors. Risk scores were created based on weighted regression coefficients. OS scores range from 0-10 (0 representing best OS), and DF risk scores range from 0-5 (0 representing lowest risk of DF). Predictive power was evaluated using c-index statistics. Bootstrapping with 200 resamples tested model stability.

resultsThe median OS was 8.1 months from SRS, and 54 (70.1 %) patients had DF at a median of 3.3 months. Risk scores for OS were predicated on performance status, extracranial disease (ED) status, number of lesions, and gender. Median OS for the low-risk group (0-3 points) was not reached. For the moderate-risk (4-6 points) and high-risk (6.5-10) groups, median OS was 7.6 months and 2.4 months, respectively (p < .0001). Scores for DF were predicated on performance status, ED status, and number of lesions. Median time to DF for the low-risk group (0 points) was not reached. For the moderate-risk (1-2 points) and high-risk (3-5 points) groups, time to DF was 4.8 and 2.0 months, respectively (p < .0001). The novel scores were more predictive (c-index = 0.72) than melanoma-specific graded prognostic assessment or RTOG recursive partitioning analysis tools (c-index = 0.66 and 0.57, respectively).

conclusionsWe devised novel risk scores for MBM treated with SRS alone. These scores have implications for prognosis and treatment strategy selection (SRS versus whole-brain radiotherapy).

Indexed as

AdultAgedAged, 80 and overBrain NeoplasmsFemaleHumansKaplan-Meier EstimateMaleMelanomaMiddle AgedPrognosisProportional Hazards ModelsRadiosurgeryRetrospective StudiesRisk FactorsSkin Neoplasms

Identifiers

PMID26626714
PMCPMC4666036
OpenAlexW2181592619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.